Literature DB >> 6607840

Neurotoxicity of the meperidine analogue N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurons in the mouse.

H Hallman, L Olson, G Jonsson.   

Abstract

The effect of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (NMPTP) on central monoamine neurons in mice was investigated using histo- and biochemical techniques. NMPTP (2 X 10 mg/kg i.v.) produced a rapid and long-lasting reduction (-30%) of striatal dopamine, while the dopamine levels were only transiently reduced in mesencephalon and frontal cortex. HVA and DOPAC were initially markedly reduced (-50 to -70%) in striatum while a marked recovery was found in the chronic stage. NMPTP also induced a long-term reduction of noradrenaline in striatum and frontal cortex while 5-hydroxytryptamine and 5-HIAA levels were essentially unaltered. The data indicate a neurotoxic action of NMPTP on both dopamine and noradrenaline nerve terminals in mouse brain.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6607840     DOI: 10.1016/0014-2999(84)90521-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  22 in total

1.  Age- and duration-dependent effects of MPTP on cortical serotonin systems.

Authors:  Twum A Ansah; Marcus C Ferguson; Tultul Nayyar; Ariel Y Deutch
Journal:  Neurosci Lett       Date:  2011-09-21       Impact factor: 3.046

2.  Restoration and putative protection in Parkinsonism.

Authors:  T Archer; A Fredriksson
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

3.  Selective decrease of immunoreactive tyrosine hydroxylase in nigrostriatum of adult male rats after N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment.

Authors:  L L Vacca-Galloway; R Ikeda; S Y Coleman
Journal:  Cell Tissue Res       Date:  1988-07       Impact factor: 5.249

4.  Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration.

Authors:  G Muthian; V Mackey; J King; C G Charlton
Journal:  Neuroscience       Date:  2010-06-09       Impact factor: 3.590

5.  Experimental Parkinson's disease in monkeys. Effect of ergot alkaloid derivative on lipid peroxidation in different brain areas.

Authors:  F Marzatico; C Café; M Taborelli; G Benzi
Journal:  Neurochem Res       Date:  1993-10       Impact factor: 3.996

6.  Short-term manganese pretreatment partially protects against 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity.

Authors:  P Rojas; C Ríos
Journal:  Neurochem Res       Date:  1995-10       Impact factor: 3.996

Review 7.  Kynurenines in Parkinson's disease: therapeutic perspectives.

Authors:  Dénes Zádori; Péter Klivényi; József Toldi; Ferenc Fülöp; László Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2011-08-20       Impact factor: 3.575

8.  Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity.

Authors:  S Przedborski; V Jackson-Lewis; R Yokoyama; T Shibata; V L Dawson; T M Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

9.  Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: characterization and localization of receptor binding sites in rat and human brain.

Authors:  J A Javitch; G R Uhl; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

10.  Electrophysiological and neurochemical correlates of the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in the mouse.

Authors:  G Jonsson; E Sundström; I Mefford; L Olson; S Johnson; R Freedman; B Hoffer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-10       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.